Volume 3.04 | Feb 3

Cord Blood News 3.04, February 3, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events


Notch-Mediated Expansion of Human Cord Blood Progenitor Cells Capable of Rapid Myeloid Reconstitution
Researchers report the development of a clinically relevant Notch-mediated ex vivo expansion system for human CD34+ cord blood progenitors that results in a marked increase in the absolute number of stem/progenitor cells, including those capable of enhanced repopulation in the marrow of immunodeficient nonobese diabetic-severe combined immunodeficient mice. [Nat Med]



Facebook Cell Therapy News is now on Facebook. Join us!

Twitter Follow us on Twitter! @Cord_Blood_News

Interested in recruiting talented individuals? Post your career opportunities in Cord Blood News at no cost. Contact us at [email protected]


Early Infusion of Donor T Regulatory Cells Prevents Graft-versus-Host Disease and Enhances Immune Recovery in High-Risk Blood Cancer Patients
A new study highlights updated results for a potential new strategy for preventing graft-versus-host disease and promoting the patient’s immune system recovery after hematopoietic stem cell transplantation. [Press release from the American Society of Hematology discussing online prepublication in Blood]

Researchers Develop Safer Way to Make Induced Pluripotent Stem Cells
Researchers have found a better way to create induced pluripotent stem cells from a small blood sample (human adult blood or umbilical cord blood). This new method avoids creating DNA changes that could lead to tumor formation. [Press release from Johns Hopkins Medicine discussing online prepublication in Cell Research]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Tregs Prevent GvHD and Promote Immune Reconstitution in HLA-Haploidentical Transplantation
The present study evaluated the impact of early infusion of Tregs, followed by conventional T cells, on GvHD prevention and immunological reconstitution, in 28 patients with high risk hematological malignancies who underwent HLA-haploidentical hematopoietic stem cell transplantation. [Blood]

Hoxb4-YFP Reporter Mouse Model: A Novel Tool for Tracking HSC Development and Studying the Role of Hoxb4 in Hematopoiesis
Hoxb4 expression does not appear to correlate with the cycling status of fetal liver hematopoietic stem cells (HSCs), although highly proliferative HSCs from young bone marrow show strong Hoxb4 expression. [Blood]

Efficient Human iPS Cell Derivation by a Non-Integrating Plasmid from Blood Cells with Unique Epigenetic and Gene Expression Signatures
The analysis suggested that newborn cord blood and adult peripheral blood mononuclear cells (MNCs) display unique signatures that are closer to induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs) than age-matched fibroblasts to iPSCs/ESCs, thus making blood MNCs an attractive cell choice for the generation of integration-free iPSCs. [Cell Res]

Chondrogenesis from Human Placenta-Derived Mesenchymal Stem Cells (hPMSCs) in 3D Scaffolds for Cartilage Tissue Engineering
It was concluded that the alginate/nano-sized calcium deficient hydroxyapatite/arginine-glycine-aspartate mixed gel in the aforementioned system could provide a 3D environment for the chondrogenesis of human placenta-derived mesenchymal stem cells, while the poly(D,L-lactide-co-glycolide) precision scaffold could provide the dimensional stability of the whole construct. [Tissue Eng Part A]

Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease
Results suggest that only cord blood units containing an expected infused cell dose greater than 5×107/kg should be considered for transplantation for hemoglobinopathy. [Biol Blood Marrow Transplant]

Total Colony Forming Units Are a Strong Independent Predictor of Neutrophil and Platelet Engraftment After Unrelated Umbilical Cord Blood Transplantation: A Single Center Analysis of 435 Cord Blood Transplants
CFU dose is a strong independent predictor of engraftment after unrelated umbilical cord blood transplantation and should be used to assess potency when selecting cord blood units for transplantation. [Biol Blood Marrow Transplant]

Favorable Outcome of Unrelated Cord Blood Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Researchers analyzed the clinical outcomes of 20 Philadelphia chromosome-positive acute lymphoblastic leukemia patients who received unrelated cord blood transplantation (CBT) (n = 8) and unrelated bone marrow transplantation (BMT) (n  = 12). The CBT group had significantly better overall survival than the BMT group (P = 0.02). [Biol Blood Marrow Transplant]


PerkinElmer’s ViaCord Releases 200th Umbilical Cord Blood Unit for Stem Cell Treatment
PerkinElmer, Inc. announced that its family cord blood banking business, ViaCord, has released its 200th umbilical cord blood stem cell unit for treatment purposes. [PerkinElmer, Inc. Press Release]

2011 Amy Strelzer Manasevit Research Program Scholar Announced
Be The Match Foundation® and the National Marrow Donor Program® have named Sophie Paczesny, M.D., Ph.D., of the University of Michigan Medical School as the newest Scholar in the Amy Strelzer Manasevit Research Program for the Study of Post-Transplant Complications. [National Marrow Donor Program Press Release]

Learn more about Cord Blood News: Archives  |  Events  |  Subscribe  |  Contact Us